Synamp’s goal is the discovery and development of entirely new classes of antibiotics capable of selectively targeting and killing bacterial cells via novel modes of action. To do so Synamp applies a strategy aimed at…

Business incubators YES!Delft and UtrechtInc secured a position in the European top 10 of the UBI Index 2015. This international ranking list for university business incubators was released in Turin on Tuesday 27 October. In 2014…

Crossbeta and Servier announce strategic oligomer-based research collaboration in neurological diseases involving misfolded proteins Crossbeta Biosciences and Servier today announced their collaboration in several research projects involving the use of…

Recently, EPIRUS Biopharmaceuticals acquired Bioceros, a company in which Utrecht Holdings was a shareholder. Both companies profit from the acquisition, as does society. In the near future, six products, five…